McGinty, Mitch (Rutkowski)
Anti-cancer immunotherapeutic strategies have achieved heterogeneous success rates across patients, and it is unclear why this is occurring. Results from our lab have revealed polymorphisms in Toll Like Receptors can influence the efficacy of immunotherapy. Suggesting that bacterial components may impact immune cell responsiveness in the tumor microenvironment. My research focuses on understanding why TLR-deficient mice exhibit protection with immunotherapies potentially illuminating novel mechanisms of immune, cancer, and bacterial interaction within the tumor microenvironment.